GO
Loading...

GlaxoSmithKline PLC

More

  • April 24- Zimmer Holdings Inc said on Thursday it would buy rival orthopedic products maker Biomet Inc for more than $13 billion, the latest deal in a wave of consolidations in the healthcare industry. The deal is expected to take Zimmer from the fourth-largest seller of orthopedics products to No. 2, behind Johnson& Johnson.

  • LONDON, April 24- AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a claim for independence following reports of bid interest from Pfizer.

  • TOKYO/ BEIJING, April 24- Three employees at one of Marubeni Corp's grain trading unit in China have been detained, Chinese customs said on Thursday, a move prompted by allegations of tax evasion on soybean imports.

  • ZURICH, April 24- Swiss drugmaker Novartis posted a weaker-than-expected 1 percent rise in quarterly sales, underscoring the pressures from generic competition and tighter healthcare budgets that led it to announce a radical business overhaul earlier this week.

  • European stocks rebound as M&A boosts industrial shares Thursday, 24 Apr 2014 | 4:22 AM ET

    *M&A activity boosts Alstom, Scania. LONDON, April 24- European shares resumed their upward trend on Thursday as mergers and acquisitions and a solid update from France's Schneider Electric fuelled a rally in the industrial sector.

  • New drug sales help boost Novartis Q1 profit Thursday, 24 Apr 2014 | 1:56 AM ET

    GENEVA— Strong new drug sales and higher operating income helped Swiss pharmaceutical firm Novartis AG report a 24 percent rise in first-quarter profit. "Novartis delivered a solid quarter, with all divisions contributing to growth," CEO Joseph Jimenez said.

  • TOKYO/ BEIJING, April 24- Three employees at one of Marubeni Corp's grain trading units in China have been detained by authorities, the Japanese trading house said on Thursday, a move sources told Reuters was prompted by allegations the unit evaded taxes on soy bean imports.

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • LONDON, April 23- The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

  • April 23- Spectrum Pharmaceuticals Inc said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe and effective in a key mid-stage trial. Roth Capital Partners analyst Joseph Pantginis said he expects CE-Melphalan to receive full approval next year.

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • *Risk sentiment bolstered by gains in US, Europe. SYDNEY/ SINGAPORE, April 23- Asian stock markets were little moved on Wednesday after a Chinese manufacturing survey met expectations, but the Australian dollar plunged to a two-week low after data showed surprisingly low inflation in that country's economy.

  • SYDNEY, April 23- Asian shares crept higher on Wednesday following merger-driven gains in Europe and on Wall Street, though investors were wary in case coming figures on Chinese manufacturing again disappointed. MSCI's broadest index of Asia-Pacific shares outside Japan added 0.15 percent.

  • Investor pressure pushing drugmaker M&A deals Tuesday, 22 Apr 2014 | 6:41 PM ET

    Swiss drugmaker Novartis AG on Tuesday said it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Eli Lilly and Co. Meanwhile, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

  • *Netflix up after results; Facebook gains on upgrade. Netflix Inc surged 7 percent to $372.90 a day after showing strong subscriber growth, a sign the trading favorite still had room to grow despite recent concerns over its valuation.

  • US STOCKS-Earnings, healthcare help lift Wall Street Tuesday, 22 Apr 2014 | 2:03 PM ET

    *Netflix up after results, Facebook gains on upgrade. Healthcare, up 1.5 percent, was the best performing of the 10 major S&P sectors, as Allergan Inc jumped 15.8 percent to $164.48 a day after activist investor William Ackman teamed up with Canadian drugmaker Valeant Pharmaceuticals International Inc to bid for the company.

  • *Netflix results lift Wall St, deal talk buoys Europe. NEW YORK, April 22- Global equity markets rose on Tuesday, powered by solid U.S. corporate earnings and deal-making activity among European drugmakers, while the euro hovered near break-even on uncertainty whether the European Central Bank will further ease monetary policy.

  • *Eli Lilly buys Novartis' animal-health arm for $5.4 bln. PARIS, April 22- The purchase of Novartis' animal-health business will strengthen Eli Lilly's hand in emerging markets, tapping into growing demand there for protein-rich diets and household treatments for pets, a senior executive at the U.S. group said.

  • *AstraZeneca jumps 6.3 pct on M&A talk. The STOXX Europe 600 health care index rose 3.2 percent as AstraZeneca rallied on speculation about a bid approach from U.S. major Pfizer, while a deal to swap assets boosted GlaxoSmithKline and Novartis.

  • Earnings and corporate deals lift US stocks Tuesday, 22 Apr 2014 | 9:15 AM ET

    Allergan surged after Valeant Pharmaceuticals said it had teamed up with activist investor Bill Ackman to make a bid for the Botox maker. Netflix and Harley-Davidson rose sharply after reporting earnings that beat analyst's expectations.

Most Popular Video

Thursday, 24 Apr 2014 | 4:03 PM ET

Microsoft is reporting Q3 EPS of $0.68 on revenue of $20.40 billion, with CNBC's Josh Lipton.

Thursday, 24 Apr 2014 | 12:41 PM ET

CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.

Thursday, 24 Apr 2014 | 2:30 PM ET

Sell in May? It's an old cliché but the problem is it's sometimes right! But earnings keep rolling in better than expected. CNBC's Patti Domm explains.